| Literature DB >> 23493314 |
A J Lawler1, V Ricci, S J W Busby, L J V Piddock.
Abstract
OBJECTIVES: The transcriptional activator RamA regulates production of the multidrug resistance efflux AcrAB-TolC system in several Enterobacteriaceae. This study investigated factors that lead to increased expression of ramA.Entities:
Keywords: antibiotic resistance; efflux inhibitors; phenothiazines
Mesh:
Substances:
Year: 2013 PMID: 23493314 PMCID: PMC3682690 DOI: 10.1093/jac/dkt069
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.790
Strains used in this study
| Strain | Genotype | Source |
|---|---|---|
| L1407 | SL1344 pMW82 | this study |
| L1232 | SL1344 pMW82 | this study |
| L1353 | SL1344 Δ | this study |
Figure 1.Induction of ramA expression by deletion of acrB or addition of chlorpromazine. Fold change in fluorescence in SL1344 ΔacrB and SL1344 in the presence of 100 mg/L chlorpromazine relative to SL1344. Fold change was calculated from the maximum fluorescence value achieved for SL1344 after 5 h of exposure relative to SL1344 ΔacrB and SL1344 in the presence of 100 mg/L chlorpromazine at the same point. An asterisk indicates a statistically significant difference (P < 0.05). CPZ, chlorpromazine.
Figure 2.Flow cytometry of strain L1232 in the presence and absence of chlorpromazine. (a) Fold change in geometric mean of fluorescence of strain L1232. An asterisk indicates a statistically significant difference (P < 0.05) between values for L1232 and L1232 in the presence of 50 mg/L chlorpromazine after 2 h of exposure. (b) A representative histogram showing the gfp fluorescence of L1232 (unfilled) and L1232 in the presence of chlorpromazine (filled). CPZ, chlorpromazine.
Figure 3.Exposure of strain L1232 to efflux pump inhibitors, psychoactive drugs and substrates of AcrAB–TolC. Fold change in fluorescence after 5 h of exposure after the addition of: (a) CCCP, PAβN, NMP, BM-38 and the control value at the same timepoint; (b) chlorpromazine (CPZ), trifluoperazine (TRIF), orphenadrine (ORP) amitriptyline (AMI), thioridazine (THIO), sertraline (SERT), haloperidol (HAL) and the control value at the same timepoint; and (c) tetracycline (TET), minocycline (MIN), chloramphenicol (CHL), norfloxacin (NOR), ciprofloxacin (CIP), nalidixic acid (NAL), levofloxacin (LVX), trimethoprim (TMP), erythromycin (ERY), cloxacillin (CL), nafcillin (NAF), carbenicillin (CAR), cefamandole (FAM), rifampicin (RIF), doxorubicin (DXR), linezolid (LZD), novobiocin (NOV), SDS and the control value at the same timepoint. Concentrations of each compound are stated in the Results section and Table S1. An asterisk indicates a statistically significant difference (P < 0.05) between values for L1232 and L1232 in the presence of compound.